Hanx Biopharmaceuticals says HX044 enters Phase I after positive preclinical data at AACR

• Hanx Biopharmaceuticals presented four oncology R&D posters at 2026 AACR annual meeting held April 17-22 in San Diego.
• Preclinical findings supported clinical development of HX044, a CTLA-4 x CD47 program now in Phase I, with modeling suggesting a wider therapeutic window versus ipilimumab.
• Separate preclinical posters on PD-L1-focused antibody-drug conjugates, including HX116 and HX112, indicated tumor-targeted activity in 3D tumor organoid testing with potential for improved specificity versus a leading clinical comparator.
• Hanx also highlighted a 3D tumor organoid evaluation platform positioned as more predictive of in vivo anti-tumor effects than conventional 2D cell assays, aiming to streamline ADC candidate selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260424-12122784), on April 24, 2026, and is solely responsible for the information contained therein.